Purpose. The aim of this study was to determine the impact of obesity on the rate of successful sentinel lymph node (SLN) mapping in patients with uterine cancer undergoing robotic surgery, and compare SLN detection rates using indocyanine green (ICG) versus blue dye. Methods. We reviewed robotic cases undergoing SLN mapping with a cervical injection from January 2011 to December 2013 using either blue dye or ICG with nearinfrared (NIR) fluorescence imaging. Data were stratified by body mass index (BMI) and the dye used. Appropriate statistical tests were applied. Results. Overall, 472 cases were identified. Bilateral mapping was successful in 352 cases (75 %), and unilateral mapping was successful in 73 cases (15 %). Bilateral mapping was achieved in 266 (85 %) of 312 ICG cases compared with 86 (54 %) of 160 blue-dye cases (p \ 0.001). Cases with successful bilateral mapping had a median BMI of 29.8 kg/m 2 (range 16.3-65.3 kg/m 2 ); cases with no mapping had a median BMI of 34.7 kg/m 2 (range 21.4-60.4 kg/m 2 ) (p = 0.001). With increasing BMI, there was a significant decrease in successful bilateral mapping rates for both the ICG (p \ 0.001) and blue-dye groups (p = 0.041); however, the use of ICG resulted in better bilateral (p = 0.002) and overall (p = 0.011) mapping rates compared with the use of blue dye in all BMI groups. Conclusions. ICG results in a higher overall and bilateral SLN detection than blue dye in women with uterine cancer. Successful mapping decreases with increasing BMI irrespective of the dye used; however, it is significantly improved with the use of ICG and NIR fluorescence imaging compared with blue dye.
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Sentinel lymph node (SLN) mapping in combination with pathologic ultrastaging has gained increasing acceptance in the surgical staging of uterine cancer. According to the most recent National Comprehensive Cancer Network (NCCN) guidelines, a published SLN algorithm incorporating ultrastaging may be considered for the surgical staging of select patients with apparent uterine-confined endometrial cancer. 1 However, the techniques involved in the SLN approach in regard to injection site and preferred dye are still debatable and evolving. Several reports describe the feasibility and detection rates of SLN mapping using various colorimetric imaging with blue dyes and/or radiocolloid mapping with technetium. 2 Bilateral mapping rates of 40 % have been reported with the use of blue dye alone, 3 and 69 % with blue dye and radioisotope. 4 Radiocolloid mapping has disadvantages compared with mapping with blue dye or indocyanine green (ICG) dye as far as the need to coordinate with the nuclear imaging department, potential pain on injection, and exposure to radiation. ICG has recently been used with near-infrared (NIR) fluorescence imaging for lymphatic mapping, and has been shown to be safe, with a low risk of allergic reactions. 5 Recent publications have shown increased success rates for bilateral and overall mapping using ICG dye versus blue dye in patients with uterine cancer; 6, 7 however, these same publications have reported decreasing SLN mapping rates with increasing body mass index (BMI). Of note, the study by Sinno and colleagues 6 showed this negative association with the use of blue dye only, and not with ICG. In the current study, we sought to retrospectively investigate the impact of obesity on the rate of successful SLN mapping in patients with uterine cancer and to compare blue dye and ICG SLN detection rates stratified by BMI.
METHODS
Institutional Review Board approval was obtained for this retrospective study. We reviewed all robotic cases undergoing SLN mapping with a cervical injection for uterine cancer and complex atypical hyperplasia from January 2011 to December 2013 using either blue dye or ICG with NIR fluorescence imaging. During the study period, our institution changed from primarily using blue dye to using ICG with NIR fluorescence imaging. Patients in whom both dyes were used have been excluded from this analysis. To avoid the possible influence of an SLN learning curve on our data, we elected to only include patients from a time period when our surgeons were experienced with the SLN technique. Our institution has performed SLN mapping since 2005. All surgeons had performed well over the previously published 30-case learning curve with SLN mapping 8 prior to this study period. Of the 472 cases in this study, our institution has previously reported on 170. 7 All cases were mapped via an intracervical injection. For cases using ICG as a fluorophobe, the concentration used was 1.25 mg/mL. For each patient, a 25-mg vial with ICG powder was diluted in 20 cc of aqueous sterile water. A total of 4 cc of this ICG solution was injected into the cervix at the 3 and 9 o'clock positions, with 1 cc injected submucosally and 1 cc injected deep into the stroma after the patient had been sterilely prepped and draped but prior to the insertion of any uterine manipulator or docking of the robot. Blue dye was injected using the same method as described for ICG. Isosulfan blue was our preferred blue dye during the study period. Our previously published SLN algorithm was followed by all surgeons (Fig. 1) , and SLNs were evaluated by pathologic ultrastaging.
Demographic and surgical data were collected. Data were stratified by BMI as normal and overweight (BMI \30), obese (BMI C30-40), and morbidly obese (BMI C40), as well as by the dye used. A subset analysis within each dye group to test mapping and BMI relationship was performed. The Fisher's exact test or Wilcoxon rank-sum test was used to test the two-way associations depending on whether a continuous variable was included or not. The mapping, BMI, and dye used (three-way association) was tested using the Cochran-Mantel-Haenszel test. SAS 9.2 or R2.3.1 statistical software was used to perform all statistical tests.
RESULTS
Overall, 472 patients with uterine cancer were identified, of whom ICG was used in 312 (66 %) cases, and blue dye was used in 160 (34 %) cases. The median age at the time Table 1 .
Of the 413 patients who had at least one SLN detected on final pathology, the median SLN count was three (range 1-15). In the 59 patients who did not have an SLN detected, the median number of lymph nodes removed was three (range 0-46). The majority of the patients who required additional lymph node dissection were in the bluedye group (61 vs. 39 % in the ICG group; p \ 0.001).
Of the 425 patients who had either bilateral or unilateral intraoperative mapping, operative time spent specifically on SLN mapping was available for 279 patients (66 %). The median SLN time was 26 min for the ICG group (range 3-98 min) and 26 min (range 6-90 min) for the blue-dye group (p = 0.984). When stratified by BMI, SLN time did significantly correlate with BMI for the entire cohort. When stratified by dye used and BMI, SLN time did not significantly correlate to BMI in the blue-dye group, and did not reach significance in the ICG group either ( Table 2) .
The median BMI for the entire cohort was 30. 2 ) (p = 0.001). A significant decrease was noted in the rate of successful bilateral mapping for both the ICG (p \ 0.001) and blue-dye groups (p = 0.041) with increasing BMI. Overall mapping also decreased with increasing BMI in the ICG (p = 0.008) and blue-dye groups (p = 0.036); however, the use of ICG resulted in significantly better bilateral (p = 0.002) and overall (p = 0.011) mapping rates compared with the use of blue dye in all BMI groups ( Table 3 ). The bilateral mapping rates for ICG and blue dye are illustrated in Fig. 2 .
DISCUSSION
More than 35 % of adult women in the US are obese (BMI C30). 9 Obesity is a major risk factor for uterine cancer and, in our study, 53 % of patients had a BMI C30. The high prevalence of obesity in this patient population makes it imperative to find reliable techniques for the surgical staging of obese and morbidly obese women in this setting. SLN mapping with pathologic ultrastaging is emerging as an acceptable approach for the surgical management of patients with uterine cancer as it has showed high nodal metastatic detection rates. 4, 10 The identification of nodal disease allows for tailored adjuvant treatment without the potential adverse effects of complete lymphadenectomy, such as increased operative time, intraoperative bleeding, length of hospital stay, and morbidity. 11 We recently reported increased bilateral and overall detection rates with the use of ICG and NIR fluorescence imaging versus blue dye in endometrial and cervical cancer. 7 We reproduced those results in this cohort of uterine cancer patients, which included a larger number of cases as a result of expanding the inclusion period. Our results also show that with increasing BMI, the rates of overall and bilateral SLN mapping decrease with the use of either ICG or blue dye. However, mapping rates were significantly improved with the use of ICG in obese and morbidly obese patients. This is reflected in the need for additional lymphadenectomy in 61 % of patients in the blue-dye group Our results demonstrate that ICG should be the dye of choice for this patient population, and that obese patients should be counseled preoperatively on their decreased mapping rates and subsequent increased likelihood of additional lymphadenectomy and its associated morbidities. Our results show that there is a significant correlation between BMI and SLN time, with an increase in SLN time with increasing BMI (Table 2) . Unfortunately, we have a limited number of patients in the group of patients with a BMI C40. Our data did not reach significance in the subset analysis of blue dye versus ICG due to sample size limitation.
The reason for the superior overall and bilateral mapping rates in the ICG group may be explained by the improved visualization of SLNs and lymphatic channels with the use of ICG and NIR fluorescence imaging compared with blue dye or the naked eye. Subserosal or submucosal injections of ICG lead to uptake by the lymphatic vessels and binding to plasma proteins. It is   FIG. 2 Bilateral mapping rate in relation to BMI. BMI body mass index, ICG indocyanine green exclusively removed by the liver and excreted through the bile without being metabolized. NIR fluorescence imaging is capable of a penetration depth of up to 1 cm in tissue. 12 Therefore, a thorough dissection to reach the lymphatic tissue is required to identify lymph channels and nodes with dye uptake. The limited, 1-cm visualization may explain the decreased SLN mapping rates in obese cases. In our study, we were unable to identify a critical cut-off point for BMI at which the mapping rate changes abruptly. We did find a gradual decrease in mapping with increasing BMI for both dyes (Fig. 2) , which may be explained by the increasing difficulty in visualizing lymphatic tissue with increasing amounts of visceral adipose tissue.
Only 15 % of our population was morbidly obese (BMI C40), and we realize some centers may see patients with significantly higher median BMIs than that reported in our study. For this subgroup, we achieved a bilateral mapping rate of 69 % and an overall mapping rate of 86 % when using ICG and NIR fluorescence imaging compared with 25 and 56 %, respectively, when using blue dye. The morbidly obese population is at increased risk for intraoperative and postoperative complications associated with prolonged operative time from a surgical and anesthesia standpoint. The advantage of an SLN approach compared with a full lymph node dissection is of particular importance in the morbidly obese, and we should continue to strive to obtain even higher rates of successful SLN mapping in these patients.
Future directions of research should examine the use of other dyes that may allow for the identification of SLNs through adipose tissue. Preclinical dyes such as CW800, a derivative of ICG, has a fluorescent intensity many times stronger than ICG, providing improved visibility in adipose tissue. CW800 can facilitate the detection of SLNs in our obese population. SIDAG [1,1( 0 )-bis-(4-sulfobutyl) indotricarbocyanine-5,5( 0 )-dicarboxylic acid diglucamide monosodium salt], another ICG derivate, is a highly hydrophilic molecule, whereas ICG is rather lipophilic. SIDAG is subsequently mainly eliminated via the renal system. Due to its low plasma protein binding and its low molecular weight, SIDAG can diffuse rapidly through pores of altered tumor vessels, and can reach deeper regions of tumor tissue in a shorter time in rat models. 13 Grossly enlarged nodes should always be removed as per our SLN algorithm as we know that high numbers of cancerous cells block the uptake of ICG.
14 The incorporation of novel dyes such as CW800 and SIDAG is nevertheless promising in regard to identifying cancerous tissue as the field evolves.
CONCLUSIONS
ICG with NIR fluorescence imaging results in higher overall and bilateral detection of SLNs in patients with uterine cancer compared with blue dye. Successful mapping decreases with increasing BMI irrespective of the dye used, but it is significantly improved with the use of ICG compared with blue dye. Based on our findings, we recommend the use of ICG for all patients with uterine cancer, particularly obese patients. As novel dyes are introduced in the evolving field of image-guided therapy, incorporating tagged molecules for the detection of tissue positive for cancer, one must ensure that dyes and molecules utilized in other patient populations such as melanoma and breast are suitable for retroperitoneal detection in the obese as these women are highly represented in the endometrial cancer population.
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